# Research Idea Ranking

**Generated:** 2026-03-06T15:40:21.683683
**Models:** GPT-5.4 (A), Gemini 3.1 Pro, GPT-5.4 (B)
**Reasoning:** high

## Comparison Table

| Idea | GPT-5.4 (A) | Gemini 3.1 Pro | GPT-5.4 (B) |
|------|------|------|------|
| How Many Generics Does It Take? Event-St... | PURSUE (68) | — | PURSUE (69) |
| Follow the Money or Follow the Crime? Po... | CONSIDER (63) | — | CONSIDER (64) |
| Deregulating Hospital Entry: Certificate... | SKIP (46) | — | SKIP (47) |
| Idea 1: How Many Generics Does It Take? ... | — | PURSUE (88) | — |
| Idea 2: Follow the Money or Follow the C... | — | CONSIDER (62) | — |
| Idea 3: Deregulating Hospital Entry: Cer... | — | SKIP (45) | — |

---

## GPT-5.4 (A)

**Tokens:** 7407

### Rankings

**#1: How Many Generics Does It Take? Event-Study Estimates of Sequential Competitor Entry on U.S. Drug Prices**
- **Score: 68/100**
- **Strengths:** This asks a first-order policy question with a direct welfare outcome: what is the marginal price effect of the 2nd, 3rd, 4th, etc. generic entrant? The data are unusually strong and the within-drug sequential-entry design is a real improvement over the older cross-sectional “more competitors vs. fewer competitors” literature.
- **Concerns:** The core threat is that entry timing is not obviously exogenous: firms enter when market conditions are favorable, shortages arise, litigation resolves, or demand changes. Also, FDA approval is not the same as actual commercial launch, and treatment mismeasurement could be serious if the event date is wrong.
- **Novelty Assessment:** **Moderate.** Generic competition and the “how many entrants lower prices?” question are heavily studied, so this is not a new topic. The novelty is in the design: a sequential within-drug event study that directly addresses market-size selection bias in the classic literature.
- **Top-Journal Potential: Medium.** A clean “more generic entry → lower prices, but only after threshold N” paper is policy-relevant and legible, and AEJ: Economic Policy is plausible. For a top-5, the bar is higher: you would need to convince readers that existing evidence is fundamentally misleading and that your design isolates competition rather than endogenous entry timing.
- **Identification Concerns:** Drug fixed effects do not solve time-varying profitability shocks that induce entry. The proposed 12-week pre-window is too short to be fully reassuring, and the paper really needs actual launch dates, not just approval dates, plus strong diagnostics around shortages, patent/litigation events, and formulation-level market definition.
- **Recommendation:** **PURSUE (conditional on: using actual market-launch dates rather than approval dates if possible; defining markets at ingredient-strength-form; expanding pre-trend diagnostics materially; and showing robustness to supply shocks/shortages and patent-resolution timing)**

---

**#2: Follow the Money or Follow the Crime? Police Resource Reallocation After Civil Asset Forfeiture Reform**
- **Score: 63/100**
- **Strengths:** This is the most novel idea in the batch and has a sharp mechanism: when a revenue-generating policing tool is weakened, do police reallocate effort across offense categories? That “revealed incentives” angle is more interesting than yet another crime-effect paper on forfeiture reform.
- **Concerns:** As currently designed, the paper risks becoming a broad state-level criminal-justice-reform DiD with noisy outcomes. Arrests reflect both police effort and underlying crime, and forfeiture reforms were often part of wider reform packages, so interpretation will be contested without a stronger first stage and better exposure variation.
- **Novelty Assessment:** **High.** Civil asset forfeiture has been studied, but mostly around crime rates, due process, and revenues. The specific substitution/resource-allocation question appears much less worked over and could be genuinely fresh.
- **Top-Journal Potential: Medium.** The upside is real because the mechanism is surprising and general: policing responds to fiscal incentives. But in its current form, it is probably not top-5 ready; it needs a tighter causal chain such as reform → forfeiture revenue falls most where pre-reform dependence was high → drug enforcement falls/other enforcement rises.
- **Identification Concerns:** Reform timing is likely endogenous to broader state politics and criminal-justice trends, and the 4-point “intensity” scale may be too ad hoc. UCR arrest data also have serious reporting and comparability issues, especially around the NIBRS transition, and the sample window misses the most recent reforms.
- **Recommendation:** **CONSIDER (best if redesigned around agency or state exposure to pre-reform forfeiture dependence, equitable-sharing loopholes, and a cleaner pre-2021 sample with reporting-quality restrictions)**

---

**#3: Deregulating Hospital Entry: Certificate of Need Repeals and the Quality-Competition Tradeoff**
- **Score: 46/100**
- **Strengths:** The policy is important and politically live, and the “entry vs. quality” tradeoff is the right welfare object. The recent partial repeals at least offer some more contemporary variation than the old repeal episodes.
- **Concerns:** This is an extremely crowded policy area, and the proposed data are not well matched to the treatment. Hospital Compare star ratings are late, coarse, and not service-line-specific, while BDS state-level hospital births/deaths are too aggregate to do much with a staggered repeal design.
- **Novelty Assessment:** **Low.** CON laws are one of the most studied health regulations in applied health economics. Using CS-DiD or star ratings does not, by itself, create much novelty.
- **Top-Journal Potential: Low.** This currently reads as “updated method on an old topic” rather than a paper that would change how the field thinks about CON. A top journal would likely ask why this is more than a competent re-estimation in a saturated literature.
- **Identification Concerns:** Many full repeals occurred long before the proposed outcome data exist, so the main treatment variation and the key outcomes barely overlap. The partial-repeal DDD has only a handful of states and the outcomes do not map cleanly to the deregulated service lines, making causal interpretation weak.
- **Recommendation:** **SKIP**

### Summary

This is a mixed batch: one solid, feasible paper with moderate upside (**Idea 1**), one higher-upside but currently underpowered/underidentified mechanism paper (**Idea 2**), and one oversaturated topic with poor data-treatment fit (**Idea 3**). I would pursue **Idea 1 first**, and keep **Idea 2** only if you can substantially strengthen the identification around actual forfeiture exposure and data quality.

---

## Gemini 3.1 Pro

**Tokens:** 5963

Here is my evaluation of the research proposals, ranked from most to least promising, applying the criteria and editorial patterns provided.

### Rankings

**#1: Idea 1: How Many Generics Does It Take? Event-Study Estimates of Sequential Competitor Entry on U.S. Drug Prices**
- **Score**: 88/100
- **Strengths**: This proposal perfectly aligns with the "first-order stakes + one sharp causal channel" winning formula by using universe-scale, high-frequency data to map a continuous marginal competition curve. It reframes a tired cross-sectional debate into a clean, dynamic event-study framework.
- **Concerns**: A 24-week post-event window might be too short to capture the full long-run equilibrium price adjustment, as pharmacy contracting and formulary updates can lag. Additionally, while the exact week of FDA approval is plausibly exogenous due to bureaucratic delays, the initial decision to file an ANDA is highly endogenous to market size.
- **Novelty Assessment**: High. While generic competition is a heavily studied topic, the *methodological approach* here is genuinely novel. Shifting from cross-sectional market comparisons (which suffer from severe selection bias) to within-drug sequential event studies is a major leap forward that has not been published in top economics journals.
- **Top-Journal Potential**: High. A top-5 journal would find this exciting because it resolves a live policy confusion (the FDA/FTC threshold debate) using universe-scale data (NADAC + Orange Book) to deliver a clean, economically legible outcome (prices). It moves beyond a simple ATE to trace out a fundamental economic object: the marginal effect of Nth-firm entry.
- **Identification Concerns**: The primary threat is anticipation effects if pharmacies or wholesalers delay purchases knowing an approval is imminent, though the 12-week pre-trend window can test this. You must also rigorously defend the assumption that the *exact week* of FDA approval is driven by idiosyncratic bureaucratic friction rather than strategic firm timing.
- **Recommendation**: PURSUE (conditional on: extending the post-event window to at least 52 weeks to capture slower-moving contracting dynamics).

**#2: Idea 2: Follow the Money or Follow the Crime? Police Resource Reallocation After Civil Asset Forfeiture Reform**
- **Score**: 62/100
- **Strengths**: The framing is excellent; it pivots away from the standard "does reform increase crime?" question to test a revealed-preference substitution mechanism (police incentive responsiveness), which top journals love. It addresses a highly salient policy debate with a clear causal chain.
- **Concerns**: State-level DiD on crime data is notoriously fragile, and the FBI UCR data is plagued by severe measurement error, missingness, and reporting inconsistencies. The 2014-2024 window perfectly overlaps with the FBI's disastrous transition from SRS to NIBRS reporting (mandated in 2021), which broke agency-level panels nationwide.
- **Novelty Assessment**: Medium-High. The specific mechanism (resource reallocation/substitution) is a fresh and clever angle on a policy that has mostly been evaluated through a narrow public-safety lens. 
- **Top-Journal Potential**: Medium. The *question* has top-journal potential because "surprising mechanisms beat another ATE" (substitution from drug to property crime). However, the *execution* will likely cap its ceiling at a field journal because reviewers will heavily discount the reliability of UCR arrest data during this specific decade.
- **Identification Concerns**: Treatment intensity coding across 37 states is inherently subjective and invites specification searching. Furthermore, changes in arrest rates might reflect changes in reporting behavior or broader criminal justice reforms (e.g., bail reform, progressive prosecutors) that occurred simultaneously in these specific states, violating parallel trends.
- **Recommendation**: CONSIDER (conditional on: abandoning UCR data in favor of high-quality, state-specific administrative court or dispatch data from a handful of treated/control states to prove the mechanism cleanly).

**#3: Idea 3: Deregulating Hospital Entry: Certificate of Need Repeals and the Quality-Competition Tradeoff**
- **Score**: 45/100
- **Strengths**: The proposal targets a clear welfare object (quality-competition tradeoff) and utilizes a within-state DDD strategy for recent partial repeals, which is structurally stronger than standard cross-state comparisons.
- **Concerns**: This reads exactly like the "competent but not exciting" papers that routinely get rejected; applying a newer estimator (CS-DiD) to a heavily saturated literature does not constitute a top-tier contribution. Furthermore, CMS Hospital Compare star ratings are widely criticized in health economics as being noisy, easily gamed by hospitals, and poorly correlated with actual clinical quality.
- **Novelty Assessment**: Low. CON laws have been studied to death for decades. The proposal's main claim to novelty is using a modern estimator (CS-DiD) and a specific CMS metric, which is an incremental, methodological update rather than a conceptual breakthrough.
- **Top-Journal Potential**: Low. As noted in the editorial patterns, leading with the estimator ("No CS-DiD in published literature") rather than a new puzzle or fact is a losing strategy. A top-5 journal will not publish a paper just because it fixes the two-way fixed effects bias in an old literature unless it drastically overturns conventional wisdom in a surprising way.
- **Identification Concerns**: For the long-run repeals (1983-2023), state-level DiD over 40 years is hopelessly confounded by thousands of other state-level healthcare shocks (Medicaid expansions, HMO penetration, ACA). For the partial repeals, N=4 treated states is likely underpowered for detecting changes in noisy star ratings.
- **Recommendation**: SKIP.

### Summary

This batch presents a clear winner in **Idea 1**, which perfectly executes the "first-order stakes + sharp causal channel" formula using universe-scale data to answer a live policy question; it should be pursued immediately. **Idea 2** has a brilliant conceptual hook (substitution effects) but is severely handicapped by the reality of UCR data quality during the 2010s-2020s, requiring a pivot to micro-data to be viable. **Idea 3** is a classic example of an incremental, estimator-driven update to a saturated literature and should be discarded to free up institutional resources.

---

## GPT-5.4 (B)

**Tokens:** 8444

### Rankings

**#1: How Many Generics Does It Take? Event-Study Estimates of Sequential Competitor Entry on U.S. Drug Prices**
- **Score: 69/100**
- **Strengths:** This has a very policy-relevant, economically legible outcome—drug prices—and the data are unusually strong. The best version of the paper could answer a live question with direct welfare stakes: whether marginal generic entry keeps lowering prices smoothly or only after a threshold number of competitors.
- **Concerns:** The core threat is that ANDA approval/entry timing is not plausibly exogenous to expected profitability, shortages, litigation resolution, or prior price trends. Also, approval is not the same as actual market launch, and short 12-week pre-trend windows are not enough for a convincing dynamic design in this setting.
- **Novelty Assessment:** **Moderate.** The broader question—how generic competition affects drug prices—is heavily studied. The proposed contribution is narrower but real: estimating within-drug marginal effects of sequential entrants rather than cross-sectional competitor counts. That is fresher, but not a new policy domain.
- **Top-Journal Potential:** **Medium.** A top field journal could plausibly want this if it convincingly shows that the canonical “number of entrants” evidence is biased by selection and that policy should target a specific competitor threshold. Top-5 potential is lower unless the paper clearly overturns accepted wisdom and nails a sharp causal chain from FDA approval policy to competition to prices.
- **Identification Concerns:** The biggest issue is endogenous entry timing: later entrants choose markets with favorable expected margins, so within-drug event timing may still be selection-driven. You also need to handle overlapping events, actual launch vs approval, and much longer pre-trend diagnostics than currently proposed.
- **Recommendation:** **PURSUE (conditional on: using actual market-launch dates or showing approval tightly maps to launch; extending pre-trend windows substantially; addressing endogenous sequential entry and overlapping-treatment bias explicitly)**

**#2: Follow the Money or Follow the Crime? Police Resource Reallocation After Civil Asset Forfeiture Reform**
- **Score: 64/100**
- **Strengths:** This is the most novel idea in the batch. The substitution framing is genuinely interesting: rather than asking whether reform affects crime, it asks whether police behavior reveals revenue-driven enforcement incentives, which is a sharper and more surprising mechanism.
- **Concerns:** Arrests are a noisy proxy for police resource allocation because they reflect both enforcement choices and underlying crime/legal changes. The data window is also a problem: many reforms are recent, while UCR comparability deteriorates late in the sample, especially around the NIBRS transition.
- **Novelty Assessment:** **High.** There is a growing literature on forfeiture reform and crime, but the specific revealed-preference/resource-reallocation question seems substantially less studied. This is meaningfully more original than the other two proposals.
- **Top-Journal Potential:** **Medium.** The upside is real because “revenue incentives distort policing” is a broad and important mechanism. But with a vanilla state-level DiD on arrest categories, it is more likely to read as suggestive than definitive; top-5 interest would require much tighter mechanism evidence.
- **Identification Concerns:** Reform timing is politically endogenous and often bundled with broader criminal-justice changes, including drug-policy reform. Changes in drug arrests may therefore reflect legalization/decriminalization or reporting changes, not police reallocation caused by forfeiture reform.
- **Recommendation:** **CONSIDER**  
  *(This moves toward PURSUE only if you can add stronger mechanism-aligned outcomes—e.g., agency-level forfeiture revenue, federal equitable-sharing participation, staffing/budget allocation, stop/search activity, or clearer offense margins less contaminated by changing criminal statutes.)*

**#3: Deregulating Hospital Entry: Certificate of Need Repeals and the Quality-Competition Tradeoff**
- **Score: 47/100**
- **Strengths:** The policy area is important and the basic welfare question is easy to understand: does entry deregulation increase supply at the cost of quality? The recent partial repeals are the only especially promising part because they potentially create within-state variation.
- **Concerns:** This literature is already crowded, and the proposed data are poorly matched to the question. Hospital Compare star ratings are noisy, relatively late, and methodologically unstable, while state-level BDS hospital births/deaths are far too aggregated to study competitive hospital entry in local markets.
- **Novelty Assessment:** **Low to moderate.** CON laws have been studied for decades. Using newer estimators or a different quality metric does not, by itself, create much novelty.
- **Top-Journal Potential:** **Low.** In current form this looks like a competent update to an old literature, not a paper that would change how the field thinks about hospital regulation. A top field journal would likely ask for better market-level entry data, stronger outcomes, and a much sharper design.
- **Identification Concerns:** Repeal timing is highly endogenous to state politics and broader health-system reforms, and the long staggered timing across few treated states makes standard DiD fragile. The partial-repeal DDD idea is more credible, but only if paired with service-line-specific outcomes and entry measures, which are not currently in hand.
- **Recommendation:** **SKIP**

### Summary

This is a decent batch, but only one idea is close to “go now.” I would **pursue Idea 1 first**, because it has the cleanest outcome, strongest data, and clearest policy payoff, though it needs serious work on the approval-vs-launch and endogenous-entry problems. **Idea 2 is the highest-novelty concept** and worth redesigning around better mechanism data; **Idea 3 is too crowded and too weakly matched on data to justify priority.**

